All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Expression of miR-155 in Acute Myeloid Leukemia and its clinical significance
Aberrant expression of microRNA-155 (miR-155) has been identified in Acute Myeloid Leukemia (AML) and may be related to clinical outcome, however, this still needs to be further characterized. Hu X. L. and Tang A. P. investigated the expression of miR-155 in bone marrow mononuclear cells (BMMNC) of 80 patients with AML and its clinical significance. Their findings were published in the Chinese Association of Pathophysiology’s Journal of Experimental Hematology.
Key Results
- MiR-155 expression levels in the moderate prognostic group and poor prognostic group were significantly higher as compared with the favorable prognosis group (P<0.05, P<0.05）
- The expression level of miR-155 did not significantly correlate with the clinical features of patients
In conclusion, although there is only a small pool of patients, overexpression of miR-155 correlated to poor prognosis in AML. However, no relationship between the levels of miR-155 and clinical features of AML was observed.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?